CD274 and hereditary clear cell renal cell carcinoma: In patients with renal cell carcinoma, salvage therapy with nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 failure had limited efficacy with a 20% ORR and a median PFS of 4.0 months.21